![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZER1 |
Gene summary for ZER1 |
![]() |
Gene information | Species | Human | Gene symbol | ZER1 | Gene ID | 10444 |
Gene name | zyg-11 related cell cycle regulator | |
Gene Alias | C9orf60 | |
Cytomap | 9q34.11 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | A0A024R8B0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10444 | ZER1 | CCI_2 | Human | Cervix | CC | 2.39e-09 | 7.69e-01 | 0.5249 |
10444 | ZER1 | CCI_3 | Human | Cervix | CC | 1.13e-07 | 5.45e-01 | 0.516 |
10444 | ZER1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.01e-10 | 4.97e-01 | -0.1954 |
10444 | ZER1 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.83e-02 | 9.48e-01 | -0.2602 |
10444 | ZER1 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.50e-11 | 5.37e-01 | -0.1464 |
10444 | ZER1 | HTA11_546_2000001011 | Human | Colorectum | AD | 2.29e-02 | 3.11e-01 | -0.0842 |
10444 | ZER1 | A015-C-203 | Human | Colorectum | FAP | 2.96e-05 | -4.51e-02 | -0.1294 |
10444 | ZER1 | A002-C-205 | Human | Colorectum | FAP | 2.89e-04 | -9.88e-02 | -0.1236 |
10444 | ZER1 | A015-C-006 | Human | Colorectum | FAP | 2.47e-02 | 1.48e-02 | -0.0994 |
10444 | ZER1 | A002-C-114 | Human | Colorectum | FAP | 8.08e-03 | -1.14e-01 | -0.1561 |
10444 | ZER1 | A015-C-104 | Human | Colorectum | FAP | 6.12e-06 | -1.08e-01 | -0.1899 |
10444 | ZER1 | A001-C-014 | Human | Colorectum | FAP | 2.83e-02 | -9.96e-02 | 0.0135 |
10444 | ZER1 | A002-C-016 | Human | Colorectum | FAP | 5.62e-04 | -1.64e-01 | 0.0521 |
10444 | ZER1 | A002-C-116 | Human | Colorectum | FAP | 4.75e-08 | -1.43e-01 | -0.0452 |
10444 | ZER1 | A014-C-008 | Human | Colorectum | FAP | 2.78e-02 | -1.91e-01 | -0.191 |
10444 | ZER1 | A018-E-020 | Human | Colorectum | FAP | 1.23e-04 | -2.20e-01 | -0.2034 |
10444 | ZER1 | F034 | Human | Colorectum | FAP | 4.93e-04 | -1.20e-01 | -0.0665 |
10444 | ZER1 | HTA12-25-1 | Human | Pancreas | PDAC | 2.54e-04 | 5.91e-01 | 0.313 |
10444 | ZER1 | HTA12-26-1 | Human | Pancreas | PDAC | 1.39e-07 | 5.71e-01 | 0.3728 |
10444 | ZER1 | HTA12-29-1 | Human | Pancreas | PDAC | 2.46e-20 | 5.90e-01 | 0.3722 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00457324 | Colorectum | FAP | positive regulation of protein catabolic process | 61/2622 | 231/18723 | 4.38e-07 | 2.35e-05 | 61 |
GO:19030504 | Colorectum | FAP | regulation of proteolysis involved in cellular protein catabolic process | 54/2622 | 221/18723 | 2.26e-05 | 5.32e-04 | 54 |
GO:00458624 | Colorectum | FAP | positive regulation of proteolysis | 81/2622 | 372/18723 | 2.64e-05 | 6.08e-04 | 81 |
GO:19033644 | Colorectum | FAP | positive regulation of cellular protein catabolic process | 40/2622 | 155/18723 | 6.94e-05 | 1.31e-03 | 40 |
GO:00324344 | Colorectum | FAP | regulation of proteasomal ubiquitin-dependent protein catabolic process | 35/2622 | 134/18723 | 1.48e-04 | 2.29e-03 | 35 |
GO:20000604 | Colorectum | FAP | positive regulation of ubiquitin-dependent protein catabolic process | 29/2622 | 107/18723 | 2.69e-04 | 3.64e-03 | 29 |
GO:19030524 | Colorectum | FAP | positive regulation of proteolysis involved in cellular protein catabolic process | 32/2622 | 133/18723 | 1.28e-03 | 1.19e-02 | 32 |
GO:00611364 | Colorectum | FAP | regulation of proteasomal protein catabolic process | 40/2622 | 187/18723 | 3.69e-03 | 2.62e-02 | 40 |
GO:00324364 | Colorectum | FAP | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 22/2622 | 90/18723 | 5.61e-03 | 3.61e-02 | 22 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZER1 | SNV | Missense_Mutation | c.1048N>A | p.Asp350Asn | p.D350N | Q7Z7L7 | protein_coding | tolerated(0.15) | benign(0.08) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
ZER1 | SNV | Missense_Mutation | c.974N>T | p.Pro325Leu | p.P325L | Q7Z7L7 | protein_coding | deleterious(0) | benign(0.435) | TCGA-C8-A12W-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
ZER1 | insertion | Frame_Shift_Ins | novel | c.1917_1918insAGCTTGGG | p.His640SerfsTer36 | p.H640Sfs*36 | Q7Z7L7 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | ||
ZER1 | insertion | Frame_Shift_Ins | novel | c.1915_1916insGCGTCCAGCTGAGCCCAAGATTTCAAGA | p.Ser639CysfsTer15 | p.S639Cfs*15 | Q7Z7L7 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | ||
ZER1 | insertion | Frame_Shift_Ins | novel | c.2163_2164insGCTTTCACTGCAGCATCTAAAATGTCACCGCCTCCAGTTCTCGAGTT | p.Ile722AlafsTer25 | p.I722Afs*25 | Q7Z7L7 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
ZER1 | SNV | Missense_Mutation | novel | c.1837N>C | p.Phe613Leu | p.F613L | Q7Z7L7 | protein_coding | deleterious(0.01) | probably_damaging(0.982) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZER1 | SNV | Missense_Mutation | rs754228946 | c.1099N>T | p.Arg367Trp | p.R367W | Q7Z7L7 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-C5-A1MP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZER1 | SNV | Missense_Mutation | novel | c.2261G>A | p.Cys754Tyr | p.C754Y | Q7Z7L7 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-C5-A3HD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
ZER1 | SNV | Missense_Mutation | novel | c.1829N>T | p.Thr610Ile | p.T610I | Q7Z7L7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-EK-A2R9-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZER1 | SNV | Missense_Mutation | novel | c.463N>C | p.Glu155Gln | p.E155Q | Q7Z7L7 | protein_coding | tolerated(0.05) | benign(0.094) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |